Bayer AG said it expects Xarelto, its new promising drug for treating and preventing stroke, to reach peak annual sales at the end of the decade, company's chief executive Marijin Dekker said in a statement.

Xarelto is a prescription medical used for reducing the risk of stroke and blood clots for atrial fibrillation patients. It is also used to treat people with pulmonary embolism and deep vein thrombosis and to help avoid any relapse.

Bayer is a global enterprise with business cores in agriculture, high-technology materials and health care. It is focused on developing products and services for the benefit of the people and to improve life quality.